• New CEO appointed, resetting priorities including improved sales pipeline and streamlined product development
• 15% ARR growth driven by 12% Q4 ARR growth, strong cost control helped deliver 78% increase in operating profit
• Signed Evolve Collaboration Agreement with NHS Confederation, 3 ACS programs underway in different countries

Beamtree Holdings Ltd reported its FY25 audited annual results, highlighting several key achievements. A new CEO was appointed in March 2025, and the company is resetting priorities, including improved sales pipeline disciplines and a streamlined product development pipeline. The company achieved 15% ARR growth for FY25, driven by 12% QoQ growth in Q4. Q4 also delivered record recurring revenue and operating profit, providing a strong foundation for Q1. Strong cost control, with only 2% YoY growth in operating expenses, helped deliver a 78% increase in operating profit and positive operating cashflow. The company signed the Evolve Collaboration Agreement with the NHS Confederation in the UK, aimed at expanding its presence in the market. It also has ACS programs underway in 3 different hospital systems in Australia, the UK, and Canada. Additionally, the company saw continued momentum with its global diagnostics partner, Abbott Inc., with a 50% increase in revenue from licenses and co-sales. The company's current pipeline provides confidence going into FY26, with a 30% increase in the later-stage sales pipeline, primarily driven by clinical coding opportunities.

The company expects ongoing improved financial performance in FY26, building on the Q4 record ARR growth and Q1 momentum, combined with relentless cost management. The company has provided confidence around a medium-term target of $60m in revenue.

The company's key product priorities for FY26 include: 1) Completing the ACS programs in Canada, the UK, and Australia, and developing a minimum viable product for scale; 2) Driving initial sales of the Integrated Coding Platform in Saudi Arabia; and 3) Executing on the Evolve Collaboration with the NHS Confederation in the UK.